8-K: Trulieve Cannabis Corp. Reports Q2 2026 Results, Lists on NYSE

Trulieve Cannabis Corp. announced its second quarter 2026 results, highlighting $271 million in revenue and a 60% gross margin, alongside its historic listing on the New York Stock Exchange.

Summary

• Trulieve Cannabis Corp. reported second quarter 2026 revenue of $271 million, with 94% derived from retail sales.
• The company achieved a gross margin of 60%, resulting in a GAAP gross profit of $162 million.
• A net loss of $406 million ($2.10 per share) was reported, largely due to a $407 million impact from the deconsolidation of Harvest operations and equity investment.
• Adjusted net income was $20 million ($0.11 per share), excluding non-recurring charges and other significant items.
• Adjusted EBITDA stood at $98 million, representing 36% of revenue.
• Cash flow from operations was $53 million, and free cash flow was $32 million for the quarter.
• The company successfully listed on the New York Stock Exchange under the ticker TRLV.
• Trulieve also announced a share repurchase program of up to $50 million.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a moderately positive report, marked by significant strategic achievements like the NYSE listing and progress in key markets, despite a reported net loss primarily due to a large deconsolidation charge.

Positives

• Revenue of $271 million for the second quarter.
• Gross margin of 60% achieved.
• Successful listing on the New York Stock Exchange (NYSE) under ticker TRLV, a significant milestone for a U.S. cannabis company.
• Filed applications to register state-licensed medical marijuana operations with the DEA following federal rescheduling to Schedule III.
• Began shipment of medical cannabis products to licensed independent pharmacies in Georgia.
• Opened four new dispensaries in Florida.
• Announced a share repurchase program of up to $50 million.
• Named to TIME's America's Best Companies 2026 List.

Negatives

• Reported a net loss attributable to common shareholders of $406 million ($2.10 per share).
• The net loss was significantly impacted by a $407 million charge related to the deconsolidation of Harvest operations and equity investment.
• Revenue decreased by 10% to $271 million compared to $302 million in the second quarter of 2025.
• Gross profit decreased by 11% to $162 million compared to $183 million in the second quarter of 2025.
• Adjusted EBITDA decreased by 11% to $98 million compared to $111 million in the second quarter of 2025.

Risks

• The company faces risks associated with the ongoing process of federal rescheduling of marijuana and its potential impact on tax burdens (Section 280E).
• Future results are subject to the successful expansion and regulatory approvals in markets like Texas.
• The deconsolidation of Harvest operations introduces complexities in financial reporting and operational oversight.
• The company is challenging the applicability of 280E tax for past tax years, with a significant uncertain tax position liability of $598 million.
• Forward-looking statements are subject to assumptions and known and unknown risks, uncertainties, and other factors that could cause actual results to differ materially.

Future Outlook

The company anticipates third quarter reported revenue will be comparable to Q2 medical revenue of $222 million. For 2026, cash flow from operations is expected to be at least $225 million (reduced from $250 million due to deconsolidation), and capital expenditures are projected up to $95 million for investments in growth markets.

Management Comments

• "We made history this quarter as the first U.S. cannabis company to list on the New York Stock Exchange following rescheduling of medical marijuana," said Kim Rivers, Trulieve CEO.
• "With broader cannabis rescheduling and state program expansion in markets like Georgia and Texas on the horizon, Trulieve is well positioned to leverage its scale, financial strength, and branded products to drive future growth."

Industry Context

StockSavvy.ai notes that Trulieve's NYSE listing is a landmark event, reflecting the evolving regulatory landscape for cannabis in the U.S. and potentially paving the way for increased institutional investment. The company's focus on medical markets and strategic expansion into states like Georgia and Texas aligns with broader industry trends of market maturation and consolidation.

Comparison to Industry Standards

• Trulieve's reported 60% gross margin is generally strong within the cannabis industry, though it has seen a slight decrease from 61% in the prior year's quarter.
• The adjusted EBITDA margin of 36% is competitive, but the reported net loss, primarily due to the large deconsolidation charge, is a significant event that requires careful investor consideration.
• The company's operational footprint of 207 retail dispensaries and 3.5 million sq ft of cultivation capacity positions it as a leading multi-state operator, comparable to other major players in the U.S. cannabis market.

Corporate Governance

Legal Proceedings

• Trulieve is challenging the applicability of Section 280E of the Internal Revenue Code for tax years 2019 through the present, with a significant uncertain tax position liability of $598 million at June 30, 2026.

Related Party Transactions

• Management services agreement receivable, related party of $22.9 million listed under assets.
• Equity in net loss of Harvest of $3.3 million noted in the statements of operations.
• The deconsolidation of Harvest involved a third-party investor, with Trulieve retaining a 90% economic interest in Harvest's mixed-use markets.

Stakeholder Impact

• Shareholders: The NYSE listing is a positive development, but the reported net loss and revenue decline may cause concern. The share repurchase program could benefit shareholders.
• Employees: Continued focus on growth initiatives and operational expansion may lead to job creation.
• Customers: Expansion of dispensaries and product offerings in markets like Georgia and Florida aims to improve access and experience.
• Creditors: The company's cash position of $325 million and debt levels will be monitored.
• Suppliers: Increased operations in Georgia and Texas could lead to greater demand for supply chain partners.

Next Steps

• Continue to support federal reform, including rescheduling and SAFE Banking.
• Support state expansion in markets like Florida, Georgia, Pennsylvania, and Texas.
• Expand production capacity and retail network in Georgia.
• Ramp up production and retail in Texas.
• Evaluate strategic M&A opportunities.
• Invest in technology and infrastructure.
• Focus on growing and retaining the customer base through exceptional experiences and brand loyalty.
• Elevate the branded product portfolio by launching new and innovative products.

Key Dates

Recommendation

The report presents a mixed picture. While the NYSE listing and strategic progress in key markets are significant positives, the decline in revenue and adjusted EBITDA, coupled with a substantial net loss driven by the Harvest deconsolidation, warrants a cautious approach. The potential benefits from federal rescheduling and market expansion are balanced by ongoing regulatory and tax uncertainties. Therefore, a 'hold' recommendation is appropriate pending clearer signs of sustained revenue growth and profitability improvement.

Keywords

Trulieve Cannabis, Cannabis Results, NYSE Listing, Medical Marijuana, Q2 Earnings, Adjusted EBITDA, Harvest Deconsolidation, Georgia Expansion